human-heparin-plasma blutgruppe a infusionslösung
drk-blutspendedienst nord-ost ggmbh - blutplasma vom menschen - infusionslösung - blutplasma vom menschen 0.ml
ms-h vaccine
pharmsure veterinary products europe ltd - mycoplasma synoviae stamm ms-h - immunologischen arzneimitteln für aves, live-bakterielle impfstoffe - hähnchen - für die aktive immunisierung von zukünftigen broilerhühnern, zukünftigen legehennenhühnern und zukünftigen legehühnern, um luftsackläsionen zu reduzieren und die anzahl von eiern mit abnormaler schalenbildung, verursacht durch mycoplasma synoviae, zu verringern.
hyogen j5 emulsion zur injektion
ceva sante animale - mycoplasma hyopneumoniae, inaktiviert - emulsion zur injektion - mycoplasma hyopneumoniae, inaktiviert - mycoplasma - schwein
ingelvac mycoflex injektionssuspension
boehringer ingelheim vetmedica - mycoplasma hyopneumoniae, inaktiviert - injektionssuspension - mycoplasma hyopneumoniae, inaktiviert - mycoplasma - schwein
mypravac suis injektionssuspension
laboratorios hipra - mycoplasma hyopneumoniae, inaktiviert - injektionssuspension - mycoplasma hyopneumoniae, inaktiviert - mycoplasma - schwein
porcilis m hyo injektionssuspension
intervet international - mycoplasma hyopneumoniae, inaktiviert - injektionssuspension - mycoplasma hyopneumoniae, inaktiviert - mycoplasma - schwein
stellamune one emulsion zur injektion
elanco - mycoplasma hyopneumoniae, inaktiviert - emulsion zur injektion - mycoplasma hyopneumoniae, inaktiviert - mycoplasma - schwein
fixr m hyo one emulsion zur injektion
kernfarm - mycoplasma hyopneumoniae, inaktiviert - emulsion zur injektion - mycoplasma hyopneumoniae, inaktiviert - mycoplasma - schwein
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - schweine - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
plasma aus apherese u-fr 0
universitätsklinikum freiburg aör (8040938) - gerinnungsaktives plasma vom menschen - infusionslösung - gerinnungsaktives plasma vom menschen (10676) 0,93 milliliter